An allergy medication eliminated food-related epinephrine use among 64 patients with alpha-gal syndrome, according to research presented in Phoenix.
Mammalian meat-eaters affected by tick bites face severe dietary restrictions and constant risks of accidental exposure. Traditional management relies completely on avoiding mammal-derived foods and products, but severe reactions still happen unexpectedly.
HCPLive reported that researchers evaluated omalizumab, an anti-immunoglobulin E monoclonal antibody, to see how it alters severe allergic outcomes in this patient population. The findings emerged on Thursday at the American College of Allergy, Asthma and Immunology annual scientific meeting.
“These findings suggest that omalizumab may offer an additional layer of protection for patients living with alpha-gal syndrome,” said Collette Tilly, lead author of the study and allergy and immunology fellow-in-training at the University of North Carolina at Chapel Hill, in a statement reported by HCPLive.
Omalizumab Targets Antibodies to Reduce Allergic Reactions
- Mechanism of Action: Omalizumab targets immunoglobulin E antibodies, neutralizing allergic pathways before they trigger systemic symptoms.
- Real-World Outcomes: Patients in the cohort took the drug for nearly two years on average, noting significant drops in reaction frequency.
- Dietary Reintegration: Roughly one in three patients successfully reintroduced at least some red meat or mammalian products without severe reactions, according to Newser.
Tilly and Colleagues Analyzed 64 Patients with Alpha-Gal Syndrome
Tilly and colleagues conducted a retrospective cohort analysis tracking 64 patients diagnosed with confirmed alpha-gal syndrome between April 2022 and November 2025, as detailed by the American College of Allergy Asthma and Immunology. Inclusion criteria required a compatible clinical history, positive alpha-gal-specific immunoglobulin E, and at least three months of follow-up.
At baseline, 52 of the 64 patients had documented anaphylaxis, and 34 required epinephrine use. During active omalizumab therapy, which spanned a median duration of 23 months with individual timelines ranging from three to 83 months, zero patients required epinephrine for food-triggered reactions, according to Bioengineer.org.
Patient-defined, clinically meaningful reductions in reaction frequency or severity were reported by 61 of the 64 participants. Mammalian food or product reintroduction was achieved by 20 patients, including full reintroduction for eight individuals and partial reintroduction for 12, per ACAAI data.
| Clinical Metric | Baseline Status (N=64) | During Omalizumab Therapy |
|---|---|---|
| Documented Anaphylaxis | 52 patients (81%) | Not tracked as baseline active |
| Epinephrine Utilization | 34 patients (53%) | 0 patients (0%) |
| Mammalian Reintroduction | 0 patients (0%) | 20 patients (31%) |
Adverse events associated with the injections were infrequent and predominantly mild, with arthralgias noted most commonly. Researchers stress that larger, rigorous prospective trials remain necessary to confirm whether most patients can safely resume eating red meat.
Diagnostic Challenges and Regional Case Rises
The study shows difficulties in identifying the tick-triggered condition quickly. Jeffrey Yu, an ACAAI member, said that individuals wait an average of seven years to receive the correct diagnosis.
“In this case, even an experienced physician didn’t think of alpha-gal at first, and that happens frequently,” Yu said, as reported by ACAAI. Case numbers continue to climb as Lone Star ticks spread to new regions across the United States.
In Tennessee, health tracking figures obtained by WZTV showed more than 627 reported cases since July 1, 2025. The condition carries a heavy psychological footprint, with two-thirds of patients reporting anxiety or depressive disorders and over half avoiding social events involving food.
Avoid Omalizumab If Hypersensitive or Facing Severe Allergic Reactions
Patients with known hypersensitivity to omalizumab or its excipients should avoid the medication entirely due to risks of anaphylaxis stemming from the biologic itself.
Individuals experiencing delayed allergic reactions hours after consuming mammalian products, or those who have suffered recurrent anaphylaxis despite strict dietary avoidance, should consult a board-certified allergist for specific immunoglobulin E blood testing. Professional medical intervention is mandatory immediately if symptoms involve difficulty breathing, throat swelling, or cardiovascular collapse requiring emergency epinephrine administration.
While the retrospective findings offer substantial promise for mitigating accidental exposure risks, experts emphasize that standard avoidance protocols remain the primary line of defense. The study has not yet appeared in a peer-reviewed journal, leaving questions open regarding optimal treatment duration and long-term remission rates after discontinuation.
“As ticks spread to more regions in the US, a simple blood test for alpha-gal could save lives,” Yu told ACAAI.
References
- American College of Allergy, Asthma and Immunology. Patients with Meat Allergy Who Take Omalizumab May See Improvement of Symptoms. November 2026.
- Bioengineer.org. Omalizumab Eliminates Food-Related Epinephrine Use in Alpha-Gal Syndrome Cohort Study. November 2026.
- Newser. A Common Drug May Help With New Red-Meat Allergy. November 2026.
- WZTV Fox 17 Investigates. Mysterious tick disease affecting a new Tennessean every day. November 2026.
